25-28 SEP 2024


25-28 SEPTEMBER 2024

Call for abstracts

We invite authors to specify if they prefer their submission to be considered for:

  • e-Poster presentation only
  • Oral presentation only
  • Indifferent

If you submit your abstract as “Oral presentation” and it does not get selected for one of the Free Communication sessions, you will still have the possibility to present it as e-poster (if the abstract is deemed acceptable).

Abstract submissions for the EADV Congress 2024 are now open

Submissions deadlines

  • Opens 20 Feb 2024
  • Closes 24 Apr 2024
Late breaking abstracts
  • Opens 13 Aug 2024
  • Closes 26 Aug 2024
  • Abstracts must be submitted in English. A “blind” selection process will be used.
  • No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
  • The title should not be written entirely in capital letters.
  • The size of the abstract is limited to 3,000 characters.
  • The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
  • Tables and figures (graphs) are allowed and they are not taken into consideration for the character count. On the other hand, pictures of patients and body parts are NOT allowed. Abstract containing pictures will be rejected.
  • In order to be able to submit your abstract you must use the template downloadable on the submission platform.
  • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
  • Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
  • No mention of pharmaceutical company names should be included in the abstract.

The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:

  • Is the content interesting, informative, novel or important?
  • Are the methods valid, the results relevant and the conclusions justified by the data?
  • Is the data presented with clarity and with appropriate structure?
  • Is the text written according to proper English grammar and syntactic style?

Submission of an abstract implies that it has been approved by all listed authors.

The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation.

As part of the submission, the author grants EADV the exclusive right to first publish the abstract, and thereafter a non-exclusive right to publish, reproduce, distribute, display and store the abstract worldwide in all forms (including on the EADV website), formats and media now known or as developed in the future, including print, electronic and digital forms. For the avoidance of doubt, “electronic and digital forms” shall include but shall not be limited to databases, USB and forms accessible via electronic and digital networks, wireless transmission and communication systems. The author also grants EADV the exclusive right to retain income resulting from the above-mentioned publications by EADV. No fee shall be paid to the author by EADV for the license granted herein. The author will retain copyright of his or her abstract, including the pertaining moral rights. However, the author shall only reuse, reproduce or post the abstract with acknowledgment to the initial and first publication or presentation at an EADV event, and therefore reference the name of the EADV event and the date.

The License of Copyright Use between EADV and the author is governed and construed in accordance with the laws of Switzerland.

Accepted abstracts will be published on our official website.

Every abstract author and meeting attendee, whether from the media, companies, institutions, organisations, universities, investment advisors, or any other category, must adhere to the embargo policy.

Embargoed materials include – but are not limited to – abstracts submitted to the EADV Events, abstracts from scientific meetings, original journal articles, written news releases, audio news releases, video news releases, interviews, slides, and any other materials associated with the scientific information being presented or published.

Embargoed materials, as well as results and information related to sessions at any meeting or event organised by EADV, are strictly confidential and cannot be disclosed in any manner or for any purpose before the lifting of the embargo by EADV.

Breaking an EADV embargo by any author, media outlet, press representative, member of staff or any third party acting on behalf of and/or under the authority of any media outlet or press representative is a contractual breach. The person/entity who released the information (i.e. the press representative who wrote the story/conducted the interview, etc.) will be held accountable and subjected to penalties.

Prior publication

If the abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the embargo policy. If publication occurs online or in print before the specific embargo date and time set by the EADV, the abstract must be withdrawn or presented as an encore. Please notify the EADV via email at

Embargo Date and Time

All abstracts:

The embargo is lifted at 7:00 CEST on 25 September 2024. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Industry abstracts:

The embargo is lifted at 7:00 CEST on 25 September 2024. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Before this date, only top-line content (no results or data) can be disclosed to announce the session content, learning outcomes and speakers.

If you have any further questions about the Scientific Programme, Abstracts, CME Accreditation, or Certificates, please contact us at


The Group Leader is entitled to process name changes at no extra costs only under these conditions:

  • The name change is requested for less than 25% of the total of purchased tickets
  • The name change is between delegates of the same registration category
  • Name changes are possible until Wednesday, 11 September 2024 only (23:59 CEST). Therefore, no name change requests are accepted after the mentioned date.

How to proceed with the name change

  1. Remove the previous attendee from your group list.
  2. Insert the new attendee in your group list
  3. Distribute the ticket to the new attendee

Ticket distribution should be managed personally by the Group Leader:

  • Before the deadline, Group Leaders can reassign a previously distributed ticket.
  • After the deadline, tickets already DISTRIBUTED cannot be re-DISTRIBUTED by the Group Leader.


Carefully read the below description to make sure you/your delegates are compliant with The Netherlands regulations.

EADV Members are not designated as Healthcare Professionals by default

Please, define the correct status (HCP or Non-HCP) during the registration process.


According to the European Union Directive 2001/83 /EC (and amended version 2010/84/EU), the promotion of prescription only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

As a multidisciplinary audience will be attending the EADV Symposium, the delegates must  indicate if they are Healthcare Professionals (HCP) or Non-Healthcare Professionals (Non-HCP) to ensure compliance with these regulations.

Access to the different areas and sessions of the Symposium depends on the status as Healthcare Professional or as Non-Healthcare Professional. 

The Pharmaceutical Research Based Industry Malta Association (2014) defines HCP as:

Any member of the medical, dental, pharmacy or nursing professions or any other person who in the course of his or her professional activities may prescribe, purchase, supply or administer a medicinal product. “

Industry sessions and advertising

Sections of the code also relevant to a congress held in Malta:

Any such promotional material (excluding promotional aids) is accompanied by a suitable statement indicating countries in which the product is registered and makes clear that the product or use is not registered locally, and any such promotional material which refers to the prescribing information (indications, warnings etc.) authorized in a country or countries where the medicinal product is registered should be accompanied by an explanatory statement indicating that registration conditions differ internationally.

Satellite Symposia presenting data on the development, research or other issues related to prescription medicine can be restricted to Healthcare Professionals and Industry Participants only upon indication provided by the Industry Session Organizer. All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs only.

Industry Session organisers could limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session. The organising company reserves the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.

The industry session organizer is responsible for the compliance of the session.

Other categories

STUDENTS are NOT considered as Healthcare Professionals under the current guidelines and will be automatically classified as NON-HEALTHCARE PROFESSIONALS.

PATIENT ASSOCIATION REPRESENTATIVES must indicate whether they are Healthcare Professionals or not at registration.